Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors
KTTA•Investor presentation highlights PAS-004 program
Pasithea highlighted PAS-004, a next-generation macrocyclic MEK1/2 inhibitor, as its lead program for NF1 and MAPK-driven solid tumors.
- Interim Phase 1 readout in advanced cancers: no dose-limiting toxicities; no ocular retinal abnormalities or cardiotoxicities; treatment-related AEs were Grade 1-2.
- Pharmacokinetics showed an estimated ~60-hour half-life in humans; cohort 7 Cmax and Cmin exceeded the cellular IC50, supporting once-daily dosing.
- Early efficacy signal: partial response in a MEK-rechallenged patient with a BRAF V600E-mutated tumor; patient remained on study at 11 months.
- Development plan centers on adult NF1 plexiform neurofibromas with interim results targeted for 2H 2026; management sized NF1-PN at $2+ billion TAM.
